Characterization of Medical Aerosols: Physical and Clinical Requirements for New Inhalers

Dolovich, Myrna

doi:10.1080/02786829408959756

Cited by 16 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An assortment of different spacer tubes, valved holding chambers and mouthpiece extensions have been developed to eliminate co‐ordination requirements, reduce the ‘cold Freon ® ’ effect (when the below‐freezing spray temperature causes some patients to stop inhaling) and reduce the amount of drug deposited in the oropharynx by decreasing the particle size distribution and slowing the aerosol's velocity. The aerosol from a MDI and holding chamber is finer than that with the MDI alone, with an approximate 25% decrease in the MMAD compared with the original aerosol [19, 20]. This finer aerosol is more uniformly distributed in the normal lung, with increased delivery to the peripheral airway.…”

Section: Pulmonary Delivery Devicesmentioning

confidence: 99%

“…By adding either a battery‐driven propeller that aids in the dispersion of the powder (Spiros; Dura Pharmaceuticals, San Diego, CA, USA) or using compressed air to aerosolize the powder and converting it into a standing cloud in a holding chamber, the generation of a respirable aerosol becomes independent of a patient's inspiratory effort (Inhance Pulmonary Delivery System, Inhale Therapeutic Systems, San Carlos, CA, USA). However, DPIs in use today are breath actuated and are dependent on a patient's IFR of 30–130 l min −1 to achieve an aerosol within the respirable range [19].…”

Section: Pulmonary Delivery Devicesmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

Labiris

Dolovich

2003

Brit J Clinical Pharma

368

218

View full text Add to dashboard Cite

Research in the area of pulmonary drug delivery has gathered momentum in the last several years, with increased interest in using the lung as a means of delivering drugs systemically. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians and health professionals will have a choice of a wide variety of device and formulation combinations that will target specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. It is now recognized that it is not enough just to have inhalation therapy available for prescribing; physicians and other healthcare providers need a basic understanding of aerosol science, inhaled formulations, delivery devices, and bioequivalence of products to prescribe these therapies optimally.

show abstract

Section: Pulmonary Delivery Devicesmentioning

confidence: 99%

Section: Pulmonary Delivery Devicesmentioning

confidence: 99%

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

Labiris

Dolovich

2003

Brit J Clinical Pharma

368

218

View full text Add to dashboard Cite

show abstract

“…The majority of currently marketed dry powder inhalers (DPIs) utilise the energy of the patient_s inspiration to generate an effective dry powder aerosol for delivery to the lungs (1). For many of these inhalers the aerosol particle size distribution is influenced by the inhaled flow rate, inspiration time and inhaled volume (2,3), and initial rate of inspiration (4Y7).…”

Section: Introductionmentioning

confidence: 99%

Influence of Realistic Inspiratory Flow Profiles on Fine Particle Fractions of Dry Powder Aerosol Formulations

2006

View full text Add to dashboard Cite

show abstract

“…[1][2][3] The MDI device, comprised of the formulation, a metering valve, container (can), and actuator, is delivered to the patient as an aerosol of fine droplets by the atomization of the liquid phase of the formulation. The driving force for atomization is provided by the evaporation of the propellant within the actuator nozzle.…”

Section: Introductionmentioning

confidence: 99%

Influence of the Storage Orientation on the Aerodynamic Particle Size of a Suspension Metered Dose Inhaler Containing Propellant HFA-227

Berry¹,

Kline²,

Hart³

et al. 2003

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

Presented in this work are the results of a study designed to investigate the impact of the storage position on the particle size distribution (PSD) of a steroid suspension metered dose inhaler (MDI) containing propellant HFA-227. It was hypothesized that the orientation of MDI samples upon storage could influence the PSD of the emitted dose, since it determines the amount of contact the liquid formulation has with the valve and therefore the quantity of nonvolatile leachable materials from the valve components that may enter the product and potentially impact the aerosol spray dynamics. Samples stored in the valve down orientation (i.e., complete contact of the liquid formulation with the valve) showed a higher level of leachables compared to those samples stored valve up (i.e., minimal contact of the formulation with the valve). The valve down samples were found to produce larger particles in the emitted aerosol spray using both cascade impaction, the preferred method of regulatory submission, as well as laser diffraction. It was postulated that the larger particle size of the inverted samples was attributed to its higher levels of leachables. Based on our findings, it is recommended that in order to set appropriate controls on the product PSD, the storage orientation of the product will need to be considered.

show abstract

Characterization of Medical Aerosols: Physical and Clinical Requirements for New Inhalers

Cited by 16 publications

References 27 publications

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

Influence of Realistic Inspiratory Flow Profiles on Fine Particle Fractions of Dry Powder Aerosol Formulations

Influence of the Storage Orientation on the Aerodynamic Particle Size of a Suspension Metered Dose Inhaler Containing Propellant HFA-227

Contact Info

Product

Resources

About